The spectrum of therapies for brain-metastatic EGFR-mutant NSCLC patients is wide, spanning multiple treatment classes; however, there is a lack of head-to-head evidence comparing EGFR-TKIs plus RT to newly emerged third-generation TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.